Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Geoffrey Y. Ku, Yelena Y. Janjigian et al.|The Lancet Oncology|2023Cited by 237
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Yoon‐Koo Kang et al.|The Lancet Oncology|2020Cited by 190
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Vivek Subbiah, Justin F. Gainor et al.|Nature Reviews Clinical Oncology|2021Cited by 140
Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trialJong-Chan Lee, Jin‐Hyeok Hwang, Dong Woo Shin et al.|Gastrointestinal Endoscopy|2020Cited by 56
First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.Kyriakos P. Papadopoulos, Glenn S. Kroog, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 38